|
Sero-prevalence in 15–49 years-old women
|
[97]
|
45.6%
|
25.2–61.0%
|
Robust French representative survey
|
|
Incidence of MPI
| |
1.0%
|
0.2–1.4%
|
Mean incidence and mean of CI lower and higher limits (expert consensus)
|
|
Transmission rate from mother to foetus
|
[19, 36, 53, 84, 87, 98,99,100]
|
40.0%
|
5.0–72.2%
|
Mean transmission rates and CI lower and higher limits from studies reporting rates by trimester of pregnancy
|
|
Transmission rate from mother to foetus (1st trimester)
|
[39, 88, 98, 101]
|
19%
|
NA
|
Mean incidence (expert consensus); screening scenario only
|
|
Transmission rate from mother to foetus (2nd trimester)
|
[39, 88, 98, 101]
|
36%
|
NA
|
Mean incidence (expert consensus); screening scenario only
|
|
Transmission rate after reinfectionb
|
[42, 102,103,104]
| | |
Unknown; assumed equal to transmission after MPI
|
|
Proportion of infected newborns who are symptom free
|
[2, 4, 105, 106]
|
87.3%
|
Min: 75.0%
|
Stable across studies
|
|
Proportion of medical TOP among MPI or infected foetus
|
[2, 4, 20, 23, 25, 39, 41, 43, 74, 88, 89, 105, 107,108,109,110,111,112,113,114,115,116,117,118,119,120]
|
9.2%
|
NA
|
Data from National Reference Laboratory and literature
|
|
Proportion of medical TOP after screening
|
[85, 103]
|
95.0%
|
NA
|
Foetal infections confirmed by amniocentesis, positive or not at echography
|
|
Prevalence of infection at birth
|
[1, 2, 4, 38, 42, 68, 69, 97, 98, 112, 121]
|
0.43%
|
0.20–0.61%
|
Min-max from European studies, vary with selection and tests
|
|
Proportion of infected newborns who are symptomatic
|
[2, 4, 88, 105, 106]
|
12.7%
|
NA
|
Do not include TOP, part of whom would have diedc
|
|
Proportion of infected newborns who are symptomatic born from mothers with immunity prior to pregnancy
|
[38, 39, 42, 105, 122]
|
12.7%
|
NA
|
Stable across studies
|
|
Incidence of hearing impairment between birth and 5 years among asymptomatic newborns with sequelae
|
[9]
|
53.0%
|
NA
| |
|
Frequency of any sequelae in asymptomatic newborns
|
[4, 11, 12, 43, 98, 106, 123, 124]
|
13.3%
|
NA
| |
|
Frequency of any severe sequelae in severe symptomatic newborns
|
[4, 9, 10, 19, 42, 43, 162, 163, 173]
|
47.0%
|
NA
|
Middle of value range
|
|
Frequency of any moderate sequela in severe symptomatic newborns
|
[4, 9, 19, 42, 43, 105, 106, 124]
|
25.0%
|
NA
|
Middle of value range
|
|
Frequency of any moderate sequela in moderately symptomatic newborns
|
[4, 9, 19, 42, 43, 105, 106, 124]
|
16.0%
|
NA
|
Middle of value range
|
|
Proportion of any severe symptomatic newborns without sequela
|
[105]
|
28.0%
|
NA
|
Middle of value range
|
|
Proportion of any moderately symptomatic newborns without sequela
|
[105]
|
51.0%
|
NA
|
Middle of value range
|
|
Frequency of any severe sequelae in moderately symptomatic newborns
|
[105]
|
33.0%
|
NA
|
Middle of value range
|
|
Proportion of any late sequelae among symptomatic newborns with sequelae
|
[105, 106, 125]
|
43.0%
|
NA
| |
|
Sensitivity IgG
|
[126,127,128]
|
99.7%
| |
Diasorin test; false negative women considered negatives, but MPI and consequences considered in truly infected women
|
|
Specificity IgG
|
[126,127,128]
|
99.4%
| |
Abbott test; false positive women considered positives, but MPI and consequences considered in truly infected women
|
|
Sensitivity IgM
|
[128,129,130,131]
|
94.0%
|
79.4–95.9%a
|
Vidas, Beckman-Coulter, Diasorin, Roche, Siemen HC tests
|
|
Specificity IgM
|
[128,129,130,131,132]
|
99.3%
|
96.4–100%a
| |
|
Sensitivity avidity of IgG
|
[23, 34, 36, 109, 131, 133,134,135,136,137,138,139,140,141,142]
|
83,0%
| |
During first 12 weeks of pregnancy; applied when IgM positive
|
|
Specificity avidity of IgG
|
[23, 34, 133,134,135,136,137,138,139,140,141,142,143]
|
82,0%
| |
During first 12 weeks of pregnancy; applied when IgM positive
|
|
Absolute reduction with hygiene
|
[63]
|
−50%
| |
Group consensus on most plausible result
|
